{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T04:45:06Z","timestamp":1792903506568,"version":"4.5.0"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Cribriform prostate cancer is associated with poor outcomes; however, its optimal treatment strategy remains unclear in the absence of randomized data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To retrospectively analyze the results of the PROTECT randomized clinical trial to establish the association between cribriform-positive and cribriform-negative prostate cancer and 15-year risk of metastasis in patients who underwent active monitoring, surgery, or radiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>Between 1999 and 2009, the PROTECT phase 3 randomized clinical trial enrolled 1643 men with clinically localized prostate cancer who were randomly assigned to receive active monitoring, surgery, or radiotherapy with neoadjuvant androgen deprivation therapy (ADT). In this secondary analysis of the PROTECT trial, a centralized histopathologic review was conducted on available diagnostic biopsy slides to classify patients as cribriform-positive if they had invasive cribriform carcinoma and\/or intraductal carcinoma. Data were collected from January 25, 2024, to October 11, 2024, and were analyzed from October 14, 2024, to January 30, 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Age, prostate-specific antigen (PSA), Gleason score, and cribriform status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome was progression to metastatic disease (bony, visceral, or lymph node metastases on imaging or PSA &amp;amp;gt;100 ng\/mL). Multivariable Cox proportional hazards regression models, adjusted for randomization variables, were incorporated to assess 15-year metastasis risk. Cumulative incidence curves were compared using the Gray test. Both intention-to-treat and per-protocol analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 712 men (mean [SD] age, 62.0 [5.0] years) whose biopsies were retrospectively reviewed, 93 (13.1%) had cribriform-positive disease and 42 (5.9%) developed metastasis. In the intention-to-treat cohort, cribriform-positive disease significantly increased the risk of metastasis (hazard ratio [HR], 3.61 [95% CI, 1.60-8.11];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.003). Radiotherapy with neoadjuvant ADT significantly reduced metastasis risk (HR, 0.35 [95% CI, 0.16-0.78];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.04) (15-year cumulative incidence in patients with cribriform-positive disease, 8%), while surgery delayed metastasis but did not significantly improve long-term outcomes compared with active monitoring (HR, 0.52 [95% CI, 0.25-1.08];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.09) (15-year cumulative incidence in patients with cribriform-positive disease, 26% for surgery and 25% for active monitoring). Among patients with cribriform-negative disease, incidence of metastasis was low and did not differ by treatment. Similar per-protocol results were noted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The findings of this secondary analysis of the PROTECT randomized clinical trial suggest that cribriform morphology was a strong, independent predictor of 15-year metastasis among patients with prostate cancer and that radiotherapy with neoadjuvant ADT was associated with a reduced long-term risk of metastasis. Conversely, outcomes were favorable for most patients with cribriform-negative disease, supporting their eligibility for active surveillance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT02044172?term=NCT02044172\">NCT02044172<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.4125","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T15:00:50Z","timestamp":1760626850000},"page":"1512","source":"Crossref","is-referenced-by-count":27,"title":["Active Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer"],"prefix":"10.1001","volume":"11","author":[{"given":"Nikita","family":"Sushentsev","sequence":"first","affiliation":[{"name":"Department of Radiology, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom"},{"name":"Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Y.","family":"Warren","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Colling","sequence":"additional","affiliation":[{"name":"Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Verrill","sequence":"additional","affiliation":[{"name":"Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Pazukhina","sequence":"additional","affiliation":[{"name":"Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Blyuss","sequence":"additional","affiliation":[{"name":"Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom"},{"name":"Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child\u2019s Health, Sechenov University, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler M.","family":"Seibert","sequence":"additional","affiliation":[{"name":"Department of Radiation Medicine and Applied Sciences, University of California San Diego, San Diego"},{"name":"Department of Urology, University of California San Diego, La Jolla"},{"name":"Department of Bioengineering, University of California San Diego Jacobs School of Engineering, La Jolla"},{"name":"Department of Radiology, University of California San Diego School of Medicine, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Barrett","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian G.","family":"Mills","sequence":"additional","affiliation":[{"name":"Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Bryant","sequence":"additional","affiliation":[{"name":"Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny L.","family":"Donovan","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Neal","sequence":"additional","affiliation":[{"name":"Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddie C.","family":"Hamdy","sequence":"additional","affiliation":[{"name":"Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10437","key":"cbr250008r1","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases.","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"issue":"15","key":"cbr250008r2","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer.","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"issue":"17","key":"cbr250008r3","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer.","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"cbr250008r4","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","article-title":"The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma.","volume":"44","author":"van Leenders","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"cbr250008r5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.5858\/arpa.2020-0015-RA","article-title":"The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer.","volume":"145","author":"Epstein","year":"2021","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"cbr250008r6","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S1470-2045(14)70361-4","article-title":"Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.","volume":"15","author":"Lane","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"cbr250008r7","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol"},{"issue":"2","key":"cbr250008r8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent.","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"issue":"1","key":"cbr250008r9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/JU.0000000000002758","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part II: principles of active surveillance, principles of surgery, and follow-up.","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"cbr250008r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.06.012","article-title":"Predicting active surveillance failure for patients with prostate cancer in the magnetic resonance imaging era: a multicentre transatlantic cohort study.","author":"Sushentsev","year":"2025","journal-title":"Eur Urol Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2840006\/jamaoncology_sushentsev_2025_br_250008_1765564202.88238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:01:02Z","timestamp":1766073662000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2840006"}},"subtitle":["A Secondary Analysis of the PROTECT Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.4125","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}